Open AccessOvarian function suppression is beneficial in some premenopausal women with early breast cancer
Author(s) -
Barton Mary Kay
Publication year - 2016
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21308
Subject(s) - exemestane , tamoxifen , breast cancer , medicine , oncology , gynecology , adjuvant , cancer , obstetrics
Key Points Premenopausal women with HR‐positive early breast cancer benefit from exemestane plus OFS versus tamoxifen with or without OFS. Results of SOFT and TEXT support the addition of OFS to exemestane or tamoxifen in premenopausal women whose risk of recurrence warrants (neo)adjuvant chemotherapy. Women with low‐risk early breast cancer derive minimal benefit from the addition of OFS.